The MIBI is dead, long live the MIBI: revisiting [99mTc]Tc-Sestamibi thyroid scintigraphy in the era of ultrasound, cytology, molecular diagnostic, and 18 F-FDG PET/CT.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 41105224.
- Also identified by DOI 10.1007/s00259-025-07567-7.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
[99mTc]Tc-sestamibi (MIBI) thyroid scintigraphy has experienced fluctuating clinical relevance, overshadowed by the rise of ultrasound, cytology, molecular diagnostics, and FDG PET/CT. However, recent evidence highlights a reinvigorated role for MIBI in specific clinical niches, notably in indeterminate thyroid nodules and iodine-induced thyroid dysfunctions. Our opinion paper synthetizes the biological background of thyroid imaging with MIBI, including semi-quantitative analysis. Current clinical indications and clinical results are discussed taking into account the emerging role of 18 F-FDG PET/CT in the field of cytologically indeterminate thyroid nodules offering a balanced perspective on integrating MIBI into modern thyroid diagnostics.
Medical subject headings
- Technetium Tc 99m Sestamibi
- Positron Emission Tomography Computed Tomography
- Fluorodeoxyglucose F18
- Thyroid Gland
- Molecular Diagnostic Techniques